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Immunotherapy for Dogs and Cats  





In recent years, immunotherapies have been brought to attention as a new form of 
human cancer treatment following surgical therapies, chemotherapies and radiotherapies. 
It was in the 1970s when immunotherapies were introduced to Japan and subsequently 
basic research outcomes have accumulated while the immunotherapies have evolved from 
its first generation to the latest fifth generation. Canine and feline cancer immunotherapies 
are said to be effective against most cancers. Especially their effects on recurrence 
prevention and metastasis control of ductal breast cancer, malignant melanoma and 
mastocytoma have been reported in many cases. 
In a past article the author summarized the first and second generation 
immunotherapies using drugs and bioactive substances and the third generation 
immunotherapies using lymphoid activation. This covered the early-phase immunotherapy 
researches from the 1970’s to early 1980’s. For the present article, the author conducted a 
literature search on action mechanisms, approaches and therapy effects of new 
immunotherapies, including cancer peptide vaccine and dendritic cell therapies, that were 
developed in and after the 1990’s ,although based on the early immunotherapies.  
In the medical field, the effectiveness of these new immunotherapies on certain types of  
cancers have been confirmed on a trial basis and some of them have been applied to actual 
canter therapies. In the veterinary field, no large-scale clinical data are available, but there 
have been a number of reports of improved QOL in animals with cancers. 
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